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To identify novel genes and pathways associated with AMD, we performed microarray gene expression
and linkage analysis which implicated the candidate gene, retinoic acid receptor-related orphan receptor
alpha (RORA, 15q). Subsequent genotyping of 159 RORA single nucleotide polymorphisms (SNPs) in a fam-
ily-based cohort, followed by replication in an unrelated case-control cohort, demonstrated that SNPs and
haplotypes located in intron 1 were signiﬁcantly associated with neovascular AMD risk in both cohorts.
This is the ﬁrst report demonstrating a possible role for RORA, a receptor for cholesterol, in the patho-
physiology of AMD. Moreover, we found a signiﬁcant interaction between RORA and the ARMS2/HTRA1
locus suggesting a novel pathway underlying AMD pathophysiology.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
The etiology of age-related macular degeneration (AMD) has yet
to be fully elucidated; nevertheless, it is clear that the development
andprogressionof this complex,multifactorial diseasemaybe inﬂu-
enced by several different pathways, including cholesterol and lipid
metabolism(for reviewsplease seeDing, Patel,&Chan,2009; Javitt&
Javitt, 2009). Epidemiologic ﬁndings have indicated a role for lipid/
cholesterol metabolism in the pathogenesis of AMD (Baker et al.,
2009; Klein, Klein, & Jensen, 1997; Tan, Wang, Flood, & Mitchell,
2009). This is further supportedbyevidence that comes fromstudies
showing that the use of cholesterol lowering drugs (statins) has all rights reserved.
phthalmology, Harvard Med-
s Street, Boston, MA 02114,
.edu (M.M. DeAngelis).protective effect against the development of neovascular AMD and
all types of AMD (McGwin, Xie, & Owsley, 2005; Wilson, Schwartz,
Bhatt, McCulloch, & Duncan, 2004); however, others have found no
signiﬁcant associationbetweenuseof thesedrugsandanyAMDsub-
types (Klein, Klein, Tomany, Danforth, & Cruickshanks, 2003; van
Leeuwen, Vingerling, Hofman, de Jong, & Stricker, 2003). Addition-
ally, both in vivo and in vitro assays have implicated a role for choles-
terol/lipidmetabolism in the development of AMD (Mullins, Russell,
Anderson, & Hageman, 2000; Sallo et al., 2009; Yamada et al., 2008;
Yu, Lorenz, Haritoglou, Kampik, & Welge-Lussen, 2009; for review
please see Ding et al., 2009).
Genetic studies have similarly implicated several lipid/choles-
terol metabolism and transport genes in the pathophysiology of
early and/or advanced stages of AMD. For example, the genes
toll-like receptors -3 and -4 (Yang et al., 2008; Zareparsi et al.,
2005), apolipoprotein E (Anderson et al., 2001; Baird, Guida, Chu,
Vu, & Guymer, 2004; Klaver et al., 1998; Schmidt et al., 2002;
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transporter (Allikmets, 2000; Allikmets et al., 1997) and the elon-
gation of very long chain fatty acids-like 4 (Conley et al., 2005)
have all been associated with risk of all AMD subtypes. However,
these ﬁndings have not been replicated consistently (Allikmets
et al., 2009; Ayyagari et al., 2001; Cho, Chew, Mitchell, & Tuo,
2009; De La Paz et al., 1999; DeAngelis et al., 2007; Despriet
et al., 2008; Edwards, Swaroop, & Seddon, 2009; Edwards et al.,
2008; Guymer et al., 2001; Haddad, Chen, Santangelo, & Seddon,
2006; Lewin, 2009; Liew, Mitchell, & Wong, 2009; Schultz et al.,
2003; Souied et al., 2000; Stone et al., 1998).
The variants and haplotypes most consistently associated with
AMD are within the gene complement factor H (CFH) (1q32) and
the locus containing the genes age-related maculopathy suscepti-
bility 2 and HtrA serine peptidase 1 (ARMS2 and HTRA1) (10q26)
(DeAngelis et al., 2008; Dewan et al., 2006; Edwards et al., 2005;
Hageman et al., 2005; Haines et al., 2005; Jakobsdottir et al.,
2005; Kanda et al., 2007; Klein et al., 2005; Li et al., 2006; Rivera
et al., 2005; Yang et al., 2006). These genes have been shown to
have large inﬂuences on AMD risk in populations of various ethnic-
ities, with variants on 10q26 being the most strongly associated
with the neovascular AMD subtype (Fisher et al., 2005; Shuler
et al., 2007; Zhang et al., 2008). Despite their large inﬂuence on
AMD risk, the combination of these genes alone is insufﬁcient to
correctly predict the development and progression of this disease
(Jakobsdottir, Gorin, Conley, Ferrell, & Weeks, 2009). While addi-
tional genes may be only minor players in terms of their contribu-
tion to the total genetic variance of AMD, effect size does not
always correlate with the importance to pathogenesis of AMD.
Additionally, because other loci do exist which have yet to be elu-
cidated (Abecasis et al., 2004; Fisher et al., 2005; Iyengar et al.,
2004; Jun et al., 2005; Kenealy et al., 2004; Majewski et al.,
2003; Schick et al., 2003; Schmidt et al., 2004; Seddon, Santangelo,
Book, Chong, & Cote, 2003), it is clear that the percent of genetic
variance is not proportional to understanding the pathophysiology
of disease or understanding gene–gene interactions. It may there-
fore be important to identify and characterize additional risk fac-
tors that may augment the value of known risk factors as
prognostic tools in order to identify individuals that require closer
follow-up and early intervention (Jakobsdottir et al., 2009; Ware,
2006). Moreover, it is equally important to determine the mecha-
nism of disease, not just risk factors, so that appropriate avenues
for treatment may be identiﬁed and explored.
Retinoic acid receptor-related orphan receptor alpha (RORA) is
one of three retinoid-related orphan receptors that compose a dis-
tinct subfamily of nuclear receptors (Hubbard et al., 2009). RORA is
known to play a key role in the regulation of circadian rhythms, the
development of cones, bone morphogenesis, angiogenesis, and
pathways including immunity/inﬂammation, lipid metabolism,
and cholesterol (Besnard et al., 2001, 2002; Boukhtouche, Mariani,
& Tedgui, 2004; Boukhtouche et al., 2006; Lau et al., 2008; Zhu,
McAvoy, Kuhn, & Smith, 2006).
In vitro studies have identiﬁed cholesterol as a natural ligand of
RORA (Kallen et al., 2002). In addition to binding cholesterol, RORA
has also been shown to regulate lipoproteins, such as high density
lipoprotein, serum amyloid A, and apolipoprotein A1 (Lau et al.,
2008; Migita, Satozawa, Lin, Morser, & Kawai, 2004; Voyiaziakis
et al., 1998). Further evidence for the role of RORA in cholesterol
(‘‘cholesteROR”) metabolism comes from phenotypic examination
of the RORA deﬁcient staggerer mouse (RORAsg) that displays an in-
creased susceptibility to arteriosclerosis and dislipidemia (Boukh-
touche et al., 2004; Jetten & Ueda, 2002; Kopmels, Mariani,
Taupin, Delhaye-Bouchaud, & Wollman, 1991; Lau et al., 2008;
Mamontova et al., 1998).
If cholesterol/lipid transport andmetabolism are involved in the
pathophysiology of neovascular AMD, then genes that are intrinsicto these pathways may be differentially expressed between pa-
tients with neovascular AMD and their unaffected siblings. In order
to identify novel candidate genes and pathways with biological rel-
evance to AMD pathophysiology, we performed linkage analysis
and gene expression microarray analysis on extremely discordant
sibling pairs. An ‘‘extreme” sibling pair consists of one sibling with
a trait value in the top 10% of disease severity and the other sibling
with a trait value in the bottom 10% of disease severity (Risch &
Zhang, 1995, 1996). Based on the results of these studies and bio-
logical plausibility in AMD etiology, the candidate gene RORA was
chosen for further analysis. Any signiﬁcant haplotypes identiﬁed in
the family-based cohort of European descent were then tested in
an unrelated case-control cohort from Central Greece.2. Methods
2.1. Family patient population
The protocol was reviewed and approved by the Institutional
Review Boards at Massachusetts Eye and Ear Inﬁrmary, Boston,
Massachusetts and conforms to the tenets of the Declaration of
Helsinki. Eligible patients were enrolled in this study after they
gave informed consent, either in person, over the phone, or
through the mail, before completing a standardized questionnaire
and donating 10–50 ml of venous blood.
Details for the recruitment of the 196 sibling pairs, comprised
mainly of individuals of European ancestry, are described else-
where (DeAngelis et al., 2008) (Population characteristics are sum-
marized in Supplementary Table 1). In brief, all index patients were
aged 50 years or older, except where one individual was 49 years
of age, and had the neovascular form of AMD in at least one eye,
deﬁned by subretinal hemorrhage, ﬁbrosis, or ﬂuorescein angio-
graphic presence of neovascularization documented at the time
of, or prior to, enrollment in the study. Patients whose only exuda-
tive ﬁnding was a retinal pigment epithelium detachment were ex-
cluded because this ﬁnding may not represent deﬁnite neovascular
AMD. Patients with signs of pathologic myopia, presumed ocular
histoplasmosis syndrome, angioid streaks, choroidal rupture, any
hereditary retinal diseases other than AMD, and previous laser
treatment due to retinal conditions other than AMD were also
excluded.
Of the 196 sibling pairs, 150 were extremely phenotypically dis-
cordant. That is pairs where the unaffected siblings had normal
maculae at an age older than that at which the index patient was
ﬁrst diagnosed with neovascular AMD. Normal maculae (deﬁned
as the zone centered at the foveola and extending two disk diam-
eters, or 3000 lm, in radius) fulﬁlled the following criteria: 0–5
small drusen (all less than 63 lm in diameter), no pigment abnor-
malities, no geographic atrophy, and no neovascularization [as de-
ﬁned previously; AMD ‘‘category 1 or less” on the Age-Related Eye
Disease Study (AREDS) scale (AREDS Research Group, 2000)]. Dis-
ease status of every participant was conﬁrmed by at least two of
the investigators by evaluation of fundus photographs or ﬂuores-
cein angiograms except when one of the investigators directly
examined an unaffected sibling during a home visit (n = 4 cases).
Smoking data, as measured in pack years, was available for every
participant.
An additional 46 discordant sibling pairs were analyzed where
each pair was comprised of one sibling (the index sibling) with
neovascular AMD and the other sibling (the control sibling) with
mild or very early AMD [AREDS category 2 (AREDS Research Group,
2000)] at 65 years of age or older in most cases. Siblings were cat-
egorized as early AMD only if they met the following criteria for
the deﬁnition of AREDS category 2: small (<63 lm) drusen with
total area P125 lm diameter circle, or at least one intermediate
700 A.C. Silveira et al. / Vision Research 50 (2010) 698–715drusen (P63 and <125 lm) or presence of pigment. These criteria
are based on published epidemiologic studies that indicate that el-
derly individuals with such maculae rarely go onto develop neo-
vascular AMD during a 10 year follow-up (Klein, Klein, Tomany,
& Moss, 2002).
2.2. Unrelated case and control population
Replication of signiﬁcant ﬁndings was performed on an unre-
lated case-control cohort from Central Greece that included pa-
tients without AMD, with early and intermediate dry AMD
[AREDS category 2 (as described above) and AREDS category 3
(n = 84); intermediate drusen comprising total area P360 lm
diameter circle in the presence of soft drusen orP656 lm diame-
ter circle in absence of soft drusen, or at least one large druse
(P125 lm), or non-Central geographic atrophy (AREDS Research
Group, 2000)] and with neovascular AMD (cases, n = 139) (Supple-
mentary Table 1). These patients were recruited from the medical
retina outpatient clinic at the University Hospital of Larissa,
Greece. The diagnosis of macular degeneration was conﬁrmed by
optical coherence tomography and ﬂuorescein angiography. Color
fundus photographs and indocyanine green angiography were per-
formed in some cases.Fig. 1. IPA-generated network containing microarray genes that were identiﬁed as signiﬁ
AMD patients and their unaffected siblings. The molecules which are colored are those th
up-regulation when comparing affected to unaffected siblings. Solid lines indicate di
previously published literature (http://www.ingenuity.com/index.html). The individual s
ligand-dependent nuclear receptor. A full listing of these proteins, their ofﬁcial name, and
3. (For interpretation of the references to colour in this ﬁgure legend, the reader is refer2.3. Microarray analysis
Total RNA isolates from transformed lymphocyte cell lines de-
rived from 18 individuals (nine sibpairs) were prepared using RNA-
easy kits (Qiagen, Valencia, CA). Each pair was matched for
smoking history, age, sex, cardiovascular disease history, body
mass index, hypertension, and hypercholesterolemia, factors that
could inﬂuence gene expression levels. RNA quality was deter-
mined by analysis using agarose gel or an Agilent 2100 Bioanalyzer
instrument (Agilent, Santa Clara, CA). Approximately 20 lg of RNA
was submitted to ampliﬁcation, labeled, and hybridized to human
Affymetrix U133A 2.0 PLUS microarrays (Affymetrix, Santa Clara,
CA) containing analytical elements corresponding to approxi-
mately 35,000+ genes.
For the gene expression microarray analysis, statistical analysis
was performed using principal component analysis (PCA) to iden-
tify substantial differences between the affected and unaffected
siblings. Further analysis was performed employing a statistical
tool referred to as robust multichip analysis (RMA). This procedure
entailed the following: (1) probe-speciﬁc correction of the probes
using a model based on observed intensity being the sum of signal
and (background) noise (Irizarry et al., 2003), (2) normalization of
corrected perfect match probes using quantile normalizationcant and that showed a greater than 2-fold difference when comparing neovascular
at were identiﬁed in our study. Green indicates down-regulation while red indicates
rect relationships and dotted lines indicate indirect relationships as identiﬁed in
hapes represent the family of molecule, for example, the shape of RORA indicates a
the family of molecules to which they belong can be found in Supplementary Table
red to the web version of this article.)
Table 1
Convergence of gene expression and genomic data.
Symbol Entrez gene name Statistical
method
Direction of fold
changea
Location Genomic convergence
evidence
CXCL13 Chemokine (C-X-C motif) ligand 13 GCRMA/LPE Up 4q21 Linkage
IL1A Interleukin 1, alpha GCRMA/LPE Up 2q14
MMP7 Matrix metallopeptidase 7 (matrilysin, uterine) GCRMA/LPE Up 11q21-
q22
PKP2 Plakophilin 2 GCRMA Down 12p11
PLA2G4A Phospholipase A2, group IVA (cytosolic, calcium-dependent) GCRMA/LPE Down 1q25 Linkage
NLRP2 NLR family, pyrin domain containing 2 GCRMA/LPE Down 19q13.42 Linkage
RGS13 Regulator of G-protein signaling 13 GCRMA/LPE Up 1q31.2 Linkage
ROBO1 Roundabout, axon guidance receptor, homolog 1
(Drosophila)
LPE Down 3p13
RORA RAR-related orphan receptor A GCRMA/LPE Down 15q21.3 Linkage
RPS6KA2 Ribosomal protein S6 kinase, 90 kDa, polypeptide 2 GCRMA/LPE Up 6q27 Linkage
Abbreviations: GCRMA, GC robust multichip analysis; LPE, local pooled error.
a Direction of change in affected compared to unaffected sibling.
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Fig. 2. Quantitative real time-PCR analysis reveals reduction of RORA expression in
AMD patients of the extremely discordant sibling pairs. The graph represents data
from ﬁve families depicting reduction of RORA expression in AMD patients relative
to their respective unaffected sibling pair; p < 0.04. Each bar is labeled with the
family identiﬁcation number and error bars indicating standard error of the mean.
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expression measures using median polish. Additional normaliza-
tion was then applied to the summarized data. The local pooled er-
ror (LPE) test was then applied to search for differentially
expressed genes. The LPE approach is similar to the Signiﬁcance
Analysis of Microarrays (SAM) method (Tusher, Tibshirani, & Chu,
2001) and the B-statistic (Lonnstedt & Speed, 2002). To account
for the multiple testing issue inherent to analysis of data from
microarray experiments, Bonferroni correction was used to control
for the family wise error rate equal to 0.05. Our results were fur-
ther conﬁrmed using a second summarizing method, which is a
variation of the RMA called GCRMA (Wu & Irizarry, 2004). Analysis
was completed using S + arrayanalyzer 2.0 from Insightful (http://
www.insightful.com).
Ingenuity Pathway Software (Ingenuity Systems, Inc., Redwood
City, CA) was used to analyze gene function and pathways/net-
works of signiﬁcant microarray genes using probe names and fold
differences between affected siblings compared to their unaffected
siblings.
2.4. Real-time quantitative polymerase chain reaction (qRT-PCR)
Total RNAwas isolated from 32 index patients and 35 unaffected
control samples that were part of the extremely discordant sibpair
cohort analyzed in both the gene expression and linkage studies,
using Trizol (Invitrogen, Carlsbad, CA). Eighty nanograms of total
RNA was reverse transcribed using SuperScript III First-Strand Syn-
thesis SuperMix (Invitrogen). One microliter of cDNA sample, and
0.5 ll probe were used in a 10 ll PCR reaction, and ﬁve replicates
were performed for each probe using Taqman Gene Expression
Master Mix (Applied Biosystems, Foster City, CA). Premade Applied
Biosystems (ABI) probes labeled with FAM were used to amplify
RORA (ABI, hs00933986_m1, hs01387931_m1, hs01387932_m1)
and b-actin (ABI, hs99999903_m1). Reactionswere quantiﬁed using
an ABI 7500 Real Time PCR instrument and analyzedwith accompa-
nying software. Relative expression levels were determined by nor-
malizing cycle threshold values for each primer to the amount of b-
actin expressed (1000/2^(Ct-gene-Ct-: b-actin). Relative fold change
was calculated from normalized values. Signiﬁcant expression dif-
ferences were assessed by the student’s paired T-Test.
2.5. Genotyping of microsatellite markers
For the genotyping of microsatellite markers, the Sequenom
iPLEX system technology, and direct sequencing protocols, leuko-
cyte DNA was either puriﬁed by using standard phenol–chloro-
form or DNAzol (Invitrogen) extraction protocols. Using 133
extremely discordant sibling pairs, we analyzed 18 highly het-erozygous microsatellite markers spanning 34 megabases of the
15q21-22 region (Supplementary Table 2). These markers in-
cluded several that were in the vicinity of RORA. All markers
were ﬂuorescently labeled with either 5-carboxyﬂuorescein or
6-carboxyﬂuorescein on the 50 end of the reverse primer and
an additional sequence of CTGTCTT was added to the 50 end of
the forward primer. PCR was used to amplify genomic DNA frag-
ments from 20 ng of leukocyte DNA in a solution of 10  PCR
buffer containing 25 mmol/L of MgCl2; 0.2 mmol/L each of deox-
yadenosine triphosphate, deoxythymidine triphosphate, deoxy-
guanosine triphosphate, and deoxycytidine triphosphate; and
0.5 U of Taq DNA polymerase (USB Corporation, Cleveland,
OH). PCR cycling conditions were as follows, 95 C for 5 min, fol-
lowed by 35 cycles of 54–60 C (speciﬁc to primer pair) for 30 s,
72 C for 30 s, and 95 C for 30 s, with a ﬁnal annealing at 54–
60 C (speciﬁc to primer pair) for 1.5 min and extension of
72 C for 5 min. Polymerase chain reaction products were diluted
1:20 for markers labeled with FAM and 1:10 for markers labeled
with HEX. Samples were pooled according to product size and
denatured before being genotyped on the ABI 3730  l DNA
Analyzer (Applied Biosystems). Data were then analyzed using
ABI’s Genemapper 3.7 software, which interrogates the quality
of the size standard and makes the appropriate genotype calls
based on size. For quality control purposes, all genotypes were
then evaluated manually.
For linkage analysis of the18microsatellitemarkers, identity-by-
state (IBS) scores were calculated from the number of alleles (0, 1 or
2) sharedbetweeneachpair, the indexand thediscordant sibling, for
each of the 18 markers. Using heterozygosities for each marker ob-
tained from Map-O-Mat (http://compgen.rutgers.edu/mapomat/),
702 A.C. Silveira et al. / Vision Research 50 (2010) 698–715the expected IBS (null hypothesis of no linkage) was calculated and
then compared with the observed IBS values. A goodness of ﬁt test
was applied to assess the signiﬁcance of the difference between
the observed and expected distribution. This method has been used
previously for linkage analysis in sibling pairs (DeAngelis et al.,
2008).
2.6. Genotyping analysis
RORA is located on chromosome 15q and spans approximately
730 kilobases. We analyzed SNP location in terms of the largest
of four transcripts, which encodes 12 exons as shown in ENSEMBLTable 3
FBAT analysis of RORA SNPs in the extremely discordant sibling pair cohort (n = 150).
Marker Allele Freq. Additive model Domi
No. of informative
families
Z score p-Value No. o
famili
rs12916023 C 0.541 65 1.709 0.0874 29
rs4583176 T 0.229 39 0.926 0.3545 33
rs730754 G 0.377 65 0.798 0.4250 46
rs8034864 A 0.216 44 0.729 0.4658 39
rs975501 G 0.390 65 1.162 0.2450 43
rs12900948 G 0.389 67 1.013 0.3113 45
rs782925 A 0.194 33 1.219 0.2230 30
rs7177611 T 0.280 47 0.762 0.4461 40
rs1403737 T 0.258 49 0.122 0.9028 41
rs12591914 T 0.303 54 0.516 0.6056 39
rs16943429 G 0.168 38 0.302 0.7630 35
rs7495128 A 0.186 40 0.295 0.7681 35
rs2414687 T 0.307 45 0.140 0.8886 39
rs17237514 G 0.156 42 1.543 0.1228 38
rs4335725 A 0.366 53 1.364 0.1724 38
rs17270640 G 0.290 50 1.069 0.2850 39
rs11071570 C 0.347 51 1.033 0.3017 37
rs6494231 A 0.399 55 1.750 0.0801 33
Abbreviations: No., Number; Freq., Frequency.
Table 2
Chromosome 15 microsatellite markers.
D15S1015 # of pairs D15S125 # of pairs D15S974 # of pairs D
# of 0’s 20 # of 0’s 12 # of 0’s 20 #
# of 1’s 56 # of 1’s 56 # of 1’s 68 #
# of 2’s 52 # of 2’s 49 # of 2’s 38 #
Total 128 Total 117 Total 126 T
# of na 5 # of na 16 # of na 7 #
h 0.905 h 0.793 h 0.969 h
Chi-sq 7.182 Chi-sq 3.180 Chi-sq 4.117 C
p-Value 0.0276 p-Value 0.2039 p-Value 0.1276 p
D15S117 # of pairs D15S209 # of pairs D15S143 # of pairs D
# of 0’s 11 # of 0’s 12 # of 0’s 11 #
# of 1’s 73 # of 1’s 75 # of 1’s 55 #
# of 2’s 35 # of 2’s 43 # of 2’s 64 #
Total 119 Total 130 Total 130 T
# of na 14 # of na 3 # of na 3 #
h 0.829 h 0.78 h 0.65 h
Chi-sq 9.208 Chi-sq 6.446 Chi-sq 1.000 C
p-Value 0.0100 p-Value 0.0398 p-Value 0.6065 p
D15S1042 # of pairs D15S118 # of pairs D15S971 # of pairs D
# of 0’s 21 # of 0’s 15 # of 0’s 17 #
# of 1’s 56 # of 1’s 68 # of 1’s 65 #
# of 2’s 49 # of 2’s 43 # of 2’s 43 #
Total 126 Total 126 Total 125 T
# of na 7 # of na 7 # of na 8 #
h 0.83 h 0.749 h 0.81 h
Chi-sq 1.263 Chi-sq 2.571 Chi-sq 1.010 C
p-Value 0.5319 p-Value 0.2765 p-Value 0.6036 p
Abbreviations: #, number; na, non-applicable; h, heterozygocity.(RORA-001: ENST00000335670) (http://www.ensembl.org/in-
dex.html). Single nucleotide polymorphisms (SNPs) were chosen
for analysis at approximately every 5000 base pairs (when varia-
tion information was available) in an effort to represent the entire
variation within the gene (Supplementary Table 2). Based on the
location of SNPs and haplotypes found to be signiﬁcantly associ-
ated with neovascular AMD, 11 TagSNPs were chosen for genotyp-
ing using the HapMap (http://www.hapmap.org/) and meeting the
following criteria: (1) a minor allele frequency greater than 10%
and (2) an r2 value that was at least 0.8 (Supplementary Table 2).
Multiplex PCR assays were designed using Sequenom Spec-
troDESIGNER software (version 3.0.0.3) (Sequenom, San Diego,nant model Recessive model
f informative
es
Z score p-Value No. of informative
families
Z score p-Value
0.557 0.5775 40 1.897 0.0578
1.219 0.2230 7 0.378 0.7055
1.180 0.2382 23 0.209 0.8348
0.801 0.4233 6 0.000 1.0000
1.372 0.1699 25 0.200 0.8415
1.043 0.2967 26 0.392 0.6949
1.826 0.0679 <4 n/a n/a
0.949 0.3428 12 0.000 1.0000
0.781 0.4349 14 1.069 0.2850
2.082 0.0374 17 2.183 0.0290
0.845 0.3980 5 1.342 0.1797
0.169 0.8658 7 1.134 0.2568
0.480 0.6310 8 1.414 0.1573
1.298 0.1944 4 1.000 0.3173
0.324 0.7456 19 2.982 0.0029
1.441 0.1495 13 0.277 0.7815
0.822 0.4111 17 0.728 0.4669
1.219 0.2230 25 1.400 0.1615
15S1036 # of pairs D15S527 # of pairs D15S643 # of pairs
of 0’s 15 # of 0’s 29 # of 0’s 25
of 1’s 71 # of 1’s 58 # of 1’s 69
of 2’s 40 # of 2’s 33 # of 2’s 37
otal 126 Total 120 Total 131
of na 7 # of na 13 # of na 2
0.848 h 0.88 h 0.872
hi-sq 4.115 Chi-sq 2.024 Chi-sq 0.848
-Value 0.1278 p-Value 0.3635 p-Value 0.6543
15S659 # of pairs D15S214 # of pairs D15S1012 # of pairs
of 0’s 23 # of 0’s 5 # of 0’s 13
of 1’s 61 # of 1’s 59 # of 1’s 71
of 2’s 40 # of 2’s 64 # of 2’s 46
otal 124 Total 128 Total 130
of na 9 # of na 5 # of na 3
0.85 h 0.43 h 0.74
hi-sq 0.043 Chi-sq 8.721 Chi-sq 3.683
-Value 0.9787 p-Value 0.0128 p-Value 0.1586
15S1232 # of pairs D15S1040 # of pairs D15S1007 # of pairs
of 0’s 27 # of 0’s 15 # of 0’s 25
of 1’s 57 # of 1’s 60 # of 1’s 68
of 2’s 35 # of 2’s 37 # of 2’s 35
otal 119 Total 112 Total 128
of na 14 # of na 21 # of na 5
0.87 h 0.77 h 0.87
hi-sq 1.165 Chi-sq 1.747 Chi-sq 1.276
-Value 0.5584 p-Value 0.4175 p-Value 0.5283
Fig. 3. Linkage disequilibrium plots for the extremely discordant sibling cohort
(n = 150 sibling pairs). Haplotype blocks were constructed in Haploview using the
method proposed by Gabriel et al. (2002). Boxes were shaded increasingly darker to
represent higher percentage of LD and the numbers listed in each square represent
the D0 (A) and r2 values (B) unless the box is completely shaded in representing
complete LD. Two haplotype blocks were generated for this cohort.
A.C. Silveira et al. / Vision Research 50 (2010) 698–715 703CA) by inputting sequence containing the SNP site and 100 base
pairs of ﬂanking sequence on either side of the SNP. Brieﬂy,
10 ng genomic DNA was ampliﬁed in a 5 ll reaction containing
1  HotStar Taq PCR buffer (Qiagen, Valencia, CA), 1.625 mM
MgCl2, 500 lm each dNTP, 100 nM each PCR primer, 0.5 U HotStar
Taq (Qiagen). The reaction was incubated at 94 C for 15 min fol-
lowed by 45 cycles of 94 C for 20 s, 56 C for 30 s, 72 C for
1 min, followed by 3 min at 72 C. Excess dNTPs were removed
from the reaction by incubation with 0.3 U shrimp alkaline phos-
phatase (USB Corporation) at 37 C for 40 min followed by a
5 min incubation at 85 C to deactivate the enzyme. Single primer
extension over the SNP was carried out in a ﬁnal concentration of
between 0.625 lm and 1.5 lm for each extension primer (depend-
ing on the mass of the probe), iPLEX termination mix (Sequenom),
and 1.35 U iPLEX enzyme (Sequenom), and cycled using a two-step
200 short cycles program; 94 C for 30 s followed by 40 cycles of
94 C for 5 s, 5 cycles of 52 C for 5 s, and 80 C for 5 s, then 72 C
for 3 min. The reaction was then desalted by addition of 6 mg cat-
ion exchange resin followed by mixing and centrifugation to settle
the contents of the tube. The extension product was then spotted
onto a 384 well SpectroCHIP (Sequenom) before being ﬂown in
the MALDI-TOF mass spectrometer. Data was collected, real time,
using SpectroTYPER Analyzer 3.3.0.15, SpectraAQUIRE 3.3.1.1 and
SpectroCALLER 3.3.0.14 (Sequenom). To ensure data quality, geno-
types for each subject were also checked manually.
For some replicate samples, direct sequencing was performed.
For these reactions, oligonucleotide primers were selected using
the Primer3 program (http://primer3.sourceforge.net/) to encom-
pass the SNP and ﬂanking intronic sequences.
All PCR assays were performed using genomic DNA fragments
from 20 ng of leukocyte DNA in a solution of 10  PCR buffer con-
taining 25 mM of MgCl2, 0.2 mM each of dATP, dTTP, dGTP, and
dCTP, and 0.5 U of Taq DNA polymerase (USB Corporation). Five
molar betaine was added to the reaction mix for rs2414687 (Sig-
ma–Aldrich, St. Louis, MO). The temperatures used during the poly-
merase chain reaction were as follows: 95 C for 5 min followed by
35 cycles of 58 C for 30 s, 72 C for 30 s and 95 C for 30 s, with a
ﬁnal annealing at 58 C for 1.5 min and extension of 72 C for
5 min. For sequencing reactions, PCR products were digested
according to manufacturer’s protocol with ExoSAP-IT (USB Corpo-
ration) then were subjected to a cycle sequencing reaction using
the Big Dye Terminator v 3.1 Cycle Sequencing kit (Applied Biosys-
tems, Foster City, CA) according to manufacturer’s protocol. Prod-
ucts were puriﬁed with Performa DTR Ultra 96-well plates (Edge
Biosystems, Gaithersburg, MD) in order to remove excess dye ter-
minators. Samples were sequenced on an ABI Prism 3100 DNA se-
quencer (Applied Biosystems). Electropherograms generated from
the ABI Prism 3100 were analyzed using the Lasergene DNA and
protein analysis software (DNASTAR, Inc., Madison, WI). Electro-
pherograms were read by two independent evaluators without
knowledge of the subject’s disease status. All patients were se-
quenced in the forward direction (50–30), unless variants or poly-
morphisms were identiﬁed, in which case conﬁrmation was
obtained in some cases by sequencing in the reverse direction.
Testing of association between SNPs and AMD in the 196 sibling
pairs was done using the family-based association test (FBAT)
(http://biosun1.harvard.edu/~fbat/fbat.htm). SNPs were tested for
association using the minor allele, as deﬁned by the allele occur-
ring less frequently in the unaffected siblings. Alleles were tested
under three genetic models: additive, dominant and recessive.
SNPs were only included for analysis in FBAT if the minor allele fre-
quency (MAF) in the affected and unaffected siblings combined
was greater than or equal to 5% and the number of informative
families was at least four. Linkage disequilibrium (LD) (both r2
and D0) between each of the SNPs was determined using the
program Haploview (http://www.broad.mit.edu/mpg/haploview/). Haplotype blocks were constructed in Haploview using the
method proposed by Gabriel et al. (2002) Individual haplotypes
were inferred and tested for association with AMD using the pro-
gram FBAT. In order to correct for multiple testing in FBAT, the per-
mutation test was used to examine each of the resulting
haplotypes.
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icant, either individually or as part of a haplotype, were calculated
in affected and separately in unaffected individuals. Deviation from
Hardy–Weinberg Equilibrium was tested on each SNP using the chi
square test.
Risk factors were controlled for using conditional logistic regres-
sion performed using SAS (SAS, version 9.1; SAS Institute Inc., Cary,
NC). Included in this analysis were those SNPs identiﬁed as signiﬁ-
cantly associated with neovascular AMD and known risk factors.
Known risk factors for the extremely discordant sibling pair cohort
included smoking history and the genetic variants CFH rs1061170
(Y402H) and ARMS2/HTRA1 rs10490924/rs11200638 (DeAngelis
et al., 2008; Zhang et al., 2008). Conditional logistic regression
was also used to test gene–gene interaction between RORA SNPs
identiﬁed as signiﬁcantly associated with AMD and the CFH and
the ARMS2/HTRA1 loci individually. Similarly, conditional logistic
regression was used to test gene–environment interaction between
RORA and smoking.
For replication in the unrelated case-control cohort from Cen-
tral Greece, single SNP analysis and haplotype analysis was per-
formed using unconditional logistic regression (UCLR) in SAS
(SAS, version 9.1; SAS Institute Inc., Cary, NC) under the same three
genetic models: additive, dominant, and recessive. Linkage dis-
equilibrium was also tested using Haploview.
2.7. Expression quantitative trait loci analysis
Using the publicly available expression quantitative trait loci
(eQTL) database mRNA by SNP Browser v 1.0.1 (Dixon et al.,
2007; Moffatt et al., 2007; Shimada et al., 2009), we investigated
the association between eQTLs and the RORA SNPs that were iden-
tiﬁed as signiﬁcant either individually or as part of a haplotype.3. Results
3.1. Patient population
Werecruited a total of 196 sibling pairs, 150 ofwhichwere extre-
melydiscordant siblingpairs (one siblingwithneovascularAMDand
one normal sibling – AREDS category 1 or less) and the remaining 46
were discordant,meaning one sibling had neovascular AMD and theTable 4
FBAT haplotype analysis of RORA in the extremely discordant sibling pair cohort (n = 150
Gabriel rule
Order rs730754 rs8034864 rs12900948
Block 1 – additive model
h1 A C A
h2 G A G
h3 G C G
Estimated haplotypes with allele frequency greater than 0.05 were listed and tested fo
value from 15,606 permutations was 0.0309.
Block 1 – dominant model
h1 A C A
h2 G A G
h3 G C G
Estimated haplotypes with allele frequency greater than 0.05 were listed and tested fo
value from 32,189 permutations was 0.0212.
Order rs17237514 rs4335725
Block 4 – recessive model
h1 A G
h2 A A
h3 G G
Estimated haplotypes with allele frequency greater than 0.05 were listed and tested fo
value from 100,000 permutations was 0.0018.
Abbreviations: No., Number; Freq., Frequency.other sibling had early dry, AMD (AREDS category 2) (Supplemen-
taryTable1). Themean ± SDageof the affected siblings (neovascular
AMD) was 72.1 ± 8.0 years (age range, 49.0–92.0 years), the age of
the mildly affected siblings (dry AMD) was 77.4 ± 7.0 years (age
range, 58.2–89.1 years), and the age of the unaffected siblings was
76.4 ± 7.8 years (age range, 50.3–94.3 years). Forty-one percent of
the unaffected siblings, 30% of the dry AMD siblings and 43% of the
matching affected siblings were male. All participants were white
and mostly of European descent.
The cohort from Central Greece consisted of a total of 344 pa-
tients: 121 normal controls, 84 early dry patients (AREDS catego-
ries 2 and 3), and 139 neovascular patients (Supplementary Table
1). The mean ± SD age of the affected subjects (neovascular AMD)
was 76.2 ± 7.4 years (age range, 49.0–94.0 years), the age of the
mildly affected subjects (dry AMD) was 74.5 ± 7.8 years (age
range, 52.0–91.0 years), and the age of the unaffected subjects
was 73.5 ± 7.3 years (age range, 48.0–88.0 years). Fifty-one per-
cent of the unaffected subjects, 44% of the AREDS category 2
and AREDS category 3 AMD subjects and 45% of the neovascular
subjects were male. All participants were white and from Central
Greece.3.2. Gene expression analysis
We compared microarray data from nine extremely discordant
sibling pairs that had been matched for smoking history, age, sex,
cardiovascular disease history, body mass index, hypertension,
and hypercholesterolemia. To create a short list of candidate genes
for further study, we used Ingenuity Pathway Analysis (IPA) soft-
ware to investigate known functions and pathways of statistically
signiﬁcant genes that were identiﬁed by either LPE or GCRMA and
had at least a 2-fold difference in expression levels. To focus our
studies, we concentrated on the IPA-generated network that
encompassed the greatest number of genes (Fig. 1 and Supplemen-
tary Table 3). Within this network, the individual genes that were
identiﬁed by LPE and GCRMA are chemokine (C-X-C motif) ligand
13 (CXCL13), interleukin 1 alpha (IL1A), matrix metallopeptidase
7 (MMP7), plakophilin 2 (PKP2), phospholipase A2 group IVA (PLA2-
G4A), NLR family, pyrin domain containing 2 (NLRP2), regulator of
G-protein signaling 13 (RGS13), roundabout, axon guidance recep-
tor, homolog 1 (Drosophila) (ROBO1), RAR-related orphan receptorpairs).
Freq. No. of informative families p-Value
0.617 74 0.3637
0.199 41 0.2652
0.159 49 0.0128
r association. When considering all possible haplotypes together, the resulting p-
0.617 35 0.9795
0.199 36 0.2073
0.159 44 0.0062
r association. When considering all possible haplotypes together, the resulting p-
Freq. No. of informative families p-Value
0.495 31 0.2142
0.359 18 0.0008
0.143 4 0.3745
r association. When considering all possible haplotypes together, the resulting p-
Table 5
Genotype and allele frequencies.
RORA Neovascular Unaffected
Frequency (%) No. Frequency (%) No.
Extremely discordant sibling pair cohort
rs730754 Genotype AA 42.18 62 35.62 52
Genotype GA 43.54 64 50.68 74
Genotype GG 14.29 21 13.70 20
Total 147 146
Allele
A 63.95 188 60.96 178
G 36.05 106 39.04 114
Total 294 292
rs8034864 Genotype CC 59.18 87 63.01 92
Genotype AC 36.73 54 32.88 48
Genotype AA 4.08 6 4.11 6
Total 147 146
Allele
C 77.55 228 79.45 232
A 22.45 66 20.55 60
Total 294 292
rs12900948 Genotype AA 39.86 59 33.56 49
Genotype GA 46.62 69 51.37 75
Genotype GG 13.51 20 15.07 22
Total 148 146
Allele
A 63.18 187 59.25 173
G 36.82 109 40.75 119
Total 296 292
rs17237514 Genotype AA 67.81 99 73.47 108
Genotype GA 29.45 43 25.17 37
Genotype GG 2.74 4 1.36 2
Total 146 147
Allele
A 82.53 241 86.05 253
G 17.47 51 13.95 41
Total 292 294
rs4335725 Genotype GG 40.14 59 40.69 59
Genotype AG 51.02 75 41.38 60
Genotype AA 8.84 13 17.93 26
Total 147 145
Allele
G 65.65 193 61.38 178
A 34.35 101 38.62 112
Total 294 290
RORA Neovascular AREDS cat. 2
Frequency (%) No. Frequency (%) No.
Discordant sibling pair cohort
rs730754 Genotype AA 40.00 18 51.11 23
Genotype GA 48.89 22 26.67 12
Genotype GG 11.11 5 22.22 10
Total 45 45
Allele
A 64.44 58 64.44 58
G 35.56 32 35.56 32
Total 90 90
rs8034864 Genotype CC 67.39 31 71.11 32
Genotype AC 26.09 12 22.22 10
Genotype AA 6.52 3 6.67 3
Total 46 45
Allele
C 80.43 74 82.22 74
A 19.57 18 17.78 16
Total 92 90
rs12900948 Genotype AA 39.13 18 44.44 20
Genotype GA 50.00 23 28.89 13
Genotype GG 10.87 5 26.67 12
Total 46 45
Allele
A 64.13 59 58.89 53
G 35.87 33 41.11 37
(continued on next page)
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Table 5 (continued)
RORA Neovascular Unaffected
Frequency (%) No. Frequency (%) No.
Total 92 90
rs17237514 Genotype AA 60.00 27 66.67 28
Genotype GA 33.33 15 28.57 12
Genotype GG 6.67 3 4.76 2
Total 45 42
Allele
A 76.67 69 80.95 68
G 23.33 21 19.05 16
Total 90 84
rs4335725 Genotype GG 50.00 23 51.11 23
Genotype AG 45.65 21 46.67 21
Genotype AA 4.35 2 2.22 1
Total 46 45
Allele
G 72.83 67 74.44 67
A 27.17 25 25.56 23
Total 92 90
RORA Neovascular AMD Dry AMD Normal
Frequency (%) No. Frequency (%) No. Frequency (%) No.
Central Greece cohort
rs730754 Genotype AA 20.49 25 35.71 30 33.62 39
Genotype GA 59.84 73 39.29 33 44.83 52
Genotype GG 19.67 24 25.00 21 21.55 25
Total 122 84 116
Allele
A 50.41 123 55.36 93 56.03 130
G 49.59 121 44.64 75 43.97 102
Total 244 168 232
rs8034864 Genotype CC 45.08 55 60.71 51 51.24 62
Genotype AC 49.18 60 28.57 24 42.98 52
Genotype AA 5.74 7 10.71 9 5.79 7
Total 122 84 121
Allele
C 69.67 170 75.00 126 72.73 176
A 30.33 74 25.00 42 27.27 66
Total 244 168 242
rs12900948 Genotype AA 9.91 11 29.49 23 30.70 35
Genotype GA 70.27 78 38.46 30 45.61 52
Genotype GG 19.82 22 32.05 25 23.68 27
Total 111 78 114
Allele
A 45.05 100 48.72 76 53.51 122
G 54.95 122 51.28 80 46.49 106
Total 222 156 228
rs17237514 Genotype AA 65.87 83 68.67 57 73.33 88
Genotype GA 33.33 42 27.71 23 25.83 31
Genotype GG 0.79 1 3.61 3 0.83 1
Total 126 83 120
Allele
A 82.54 208 82.53 137 86.25 207
G 17.46 44 17.47 29 13.75 33
Total 252 166 240
rs4335725 Genotype GG 56.35 71 60.71 51 52.89 64
Genotype AG 34.92 44 33.33 28 39.67 48
Genotype AA 8.73 11 5.95 5 7.44 9
Total 126 84 121
Allele
G 73.81 186 77.38 130 72.73 176
A 26.19 66 22.62 38 27.27 66
Total 252 168 242
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(RPS6KA2) (Table 1). This set of genes was simultaneously analyzed
with linkage data previously obtained from our laboratory to
investigate genomic convergence (Table 1).
Of these genes, RORA was selected for further study due to its
anti-angiogenic properties (Boukhtouche et al., 2004; Chauvet,Bois-Joyeux, Berra, Pouyssegur, & Danan, 2004; Chauvet et al.,
2005), the statistically different expression between affected pa-
tients compared to their unaffected siblings, and linkage data
(see Section 3.3) demonstrating an association of the 15q region
with neovascular AMD. Speciﬁcally, 4 RORA probes were identiﬁed
as signiﬁcantly altered in AMD vs. control samples. Three of these
A.C. Silveira et al. / Vision Research 50 (2010) 698–715 707probes showed decreased expression in AMD patients (p-value
ranged from 103 to 109 after Bonferonni correction) while 1
probe showed increased expression in affected patients (p = 104
after Bonferonni correction).
In order to conﬁrm the results of the microarray studies, qRT-
PCR analysis was performed on RNA from neovascular AMD pa-
tients (n = 32) and their unaffected control siblings (n = 35), which
included RNA from seven of the nine original pairs used for the
gene expression microarray analysis. The 3 RNA probes used
showed a trend of decreased RORA expression in this cohort
(>1.5-fold; data not shown). Speciﬁcally, ﬁve of the families
showed statistically signiﬁcant reduction in RORA gene expression
ranging from 2-fold reduction to as high as 16-fold reduction in an
AMD patient compared to their respective sibpair, p < 0.04 (Fig. 2).
3.3. Linkage analysis using microsatellite markers
Calculation of identity-by-state scores from the genotyping re-
sults of 18 highly heterozygous microsatellite markers in the 15q
region identiﬁed three markers, D15S1015, D15S209, and
D15S214, that were modestly associated with neovascular AMD
(p < 0.05) (Table 2). The most signiﬁcantly associated marker,
D15S117 (p = 0.01), is located approximately 2 megabases from
the gene end (RORA: ENSG00000069667) (Supplementary Table 2).3.4. Analysis of RORA SNPs and haplotypes in the extremely discordant
sibling pair cohort
In total, we identiﬁed 92 SNPs in the RORA gene demonstrating
variation in our extremely discordant sibling pair cohort (discovery
cohort) (n = 150 pairs; 300 subjects) (for SNPs and location refer to
Supplementary Table 2). No signiﬁcant deviations from Hardy–
Weinberg equilibrium for any of the variants studied were
observed in either affected or unaffected siblings, suggesting unli-
kely contamination of our dataset. Single SNP analysis using FBAT
in our discovery cohort identiﬁed rs12591914 and rs4335725,
variants located within intron 1 of the RORA-001 transcript
(ENST00000335670), as modestly (p = 0.029) and signiﬁcantly
(p = 0.0029) associated under a recessive model respectively (Table
3). The RORA SNP rs4335725 remained signiﬁcant (p 6 0.007) after
controlling for the following factors: CFH rs1061170 (Y402H),
ARMS2/HTRA1 rs10490924/rs11200638, and smoking history in a
multiple logistic regression model; however, the rs12591914 SNP
did not remain signiﬁcant (data not shown).
Haploview, using haplotype blocks deﬁned by the Gabriel rule
(Gabriel et al., 2002), demonstrated that there were 13 haplotype
blocks spanning the more than 700,000 base pairs covered by
genotyping (Supplementary Figs. 1 and 2 and Table 2). Of the 13
haplotype blocks, two blocks, both located in intron 1 and compris-
ing three haplotypes, were shown to be signiﬁcantly associated
with neovascular AMD risk in FBAT [h3 in block 1 (GCG) under both
additive (p = 0.0128) and dominant (p = 0.0062) genetic models, asTable 6
FBAT analysis of RORA SNPs in the AREDS category 2 discordant sibling pair cohort (n = 46
Marker Allele Freq. Additive model Domi
No. of informative
families
Z score p-Value No. of
famili
rs730754 G 0.348 14 0.243 0.8084 7
rs8034864 A 0.183 9 0.333 0.7389 7
rs12900948 G 0.378 13 1.000 0.3173 6
rs17237514 G 0.215 9 0.577 0.5637 9
rs4335725 A 0.261 16 0.500 0.6171 13
Abbreviations: No., Number.well as h2 in block 4 (AA) under a recessive (p = 0.0008) genetic
model (Fig. 3 and Table 4)]. The overall permutations for the ﬁrst
haplotype in block 1 under both an additive and a dominant model
was p = 0.03 and p = 0.02, respectively. The overall permutation for
the second haplotype block was p = 0.0018 under a recessive
model. Conservation analysis showed that the SNPs comprising
these two haplotypes blocks (rs730754, rs8034864, rs12900948,
rs17237514 and rs4335725) (Fig. 3) are all well conserved in both
rat and mouse. Genotype and allele frequencies for these 5 SNPs
are given in Table 5. Based on these ﬁndings, we chose 11 tagging
SNPs within intron 1 to further capture variation and reﬁne this re-
gion, which is approximately 550 kilobases, for further study. Sta-
tistical analysis using FBAT showed that none of the RORA intron 1
tagging SNPs were informative individually or as part of a haplo-
type as they did not remain signiﬁcantly associated with neovascu-
lar AMD after correction for multiple testing.
3.5. Analysis of RORA SNPs and haplotypes in the AREDS category 2
discordant sibling pair cohort
The 5 SNPs that comprised the two haplotype blocks contain-
ing signiﬁcant haplotypes in the discovery cohort (rs730754,
rs8034864, rs12900948, for block 1 and rs17237514 and rs433-
5725 for block 4) were tested for association in the AREDS category
2 discordant sibling pair cohort where the index patient had the
neovascular form of AMD and the matched sibling had the early/
dry form of AMD (AREDS category 2). Single SNP analysis of these
ﬁve SNPs using FBAT showed that one SNP, rs12900948, was mod-
estly associated with decreased risk of developing neovascular
AMD under a recessive genetic model (p = 0.034) (Table 6). This
SNP, like rs4335725, is also located in intron 1 of the RORA-001
transcript (ENST00000335670) and is also well conserved.
Haploview was used to create LD plots for this cohort (Fig. 4).
Like the extremely discordant sibling pairs, applying the Gabriel
rule demonstrated that block 1 containing SNPs rs730754,
rs8034864 and rs12900948 was the same between both sibling
pair cohorts studied (Figs. 3 and 4). However, the second haplo-
type block identiﬁed in the initial discovery cohort of extremely
discordant sibling pairs was not found in the AREDS category 2
discordant sibling pair cohort. This may be due to the much smal-
ler sample size analyzed (n = 46 discordant sibling pairs). FBAT
analysis of these two haplotype blocks in the AREDS category 2
discordant sibling pair cohort demonstrated that one haplotype
(ACA) within this block was modestly associated with neovascu-
lar AMD risk (p = 0.0492). However, after permutation testing this
ﬁnding was no longer signiﬁcant (p = 0.114) (Supplementary Ta-
ble 4).3.6. Analysis of RORA SNPs and haplotypes in the Greek cohort
The SNPs that comprised the signiﬁcant haplotypes (rs730754,
rs8034864, rs12900948, for block 1 and rs17237514 andpairs).
nant model Recessive model
informative
es
Z score p-Value No. of informative
families
Z score p-Value
1.890 0.0588 8 2.000 0.1573
0.378 0.7055 <4 n/a n/a
0.816 0.4142 8 3.000 0.0339
0.333 0.7389 <4 n/a n/a
0.277 0.7815 <4 n/a n/a
Fig. 4. Linkage disequilibrium plots for the AREDS 2 discordant sibling cohort
(n = 46 sibling pairs). Haplotype blocks were constructed in Haploview using the
method proposed by Gabriel et al. (2002). Boxes were shaded increasingly darker to
represent higher percentage of LD and the numbers listed in each square represent
the D0 (A) and r2 values (B) unless the box is completely shaded in representing
complete LD. A single haplotype block was generated for this cohort.
708 A.C. Silveira et al. / Vision Research 50 (2010) 698–715rs4335725 for block 4) in the discovery cohort were genotyped and
tested for association in the Greek population (n = 344) using
unconditional logistic regression. This analysis showed that only
rs12900948 was signiﬁcantly associated with neovascular AMD
when comparing neovascular AMD patients to normal patients
and separately to patients with early and intermediate dry AMD
(AREDS categories 2 and 3) under either a dominant or recessivemodel (Table 7). Speciﬁcally, the G allele (which is the minor allele
for both family-based cohorts but the major allele for the Greek co-
hort) of rs12900948 increased risk of neovascular AMD in the
unrelated case-control cohort by 4-fold and 3.8-fold when com-
pared to normal patients and separately to patients with dry
AMD respectively (OR: 4.028; 95% C.I.: 1.924, 8.433; p = 0.0002
and OR: 3.802; 95% C.I.: 1.725, 8.379; p = 0.0009). When we com-
pared the G allele of rs12900948 in normal controls (AREDS
category 1 or less) to all subtypes of AMD in this unrelated case-
control cohort, this ﬁnding was much more modestly associated
(OR: 2.020; 95% C.I.: 1.172, 3.480; p = 0.0113).
Haploview analysis using the Gabriel rule showed that there
was a single haplotype block in the Greek unrelated case-control
cohort (Fig. 5). This haplotype block, containing SNPs rs730754,
rs8034864, rs12900948, was common to the cohort from Central
Greece and both family-based cohorts studied (Figs. 3–5). While
SNPs rs17237514 and rs4335725 comprised a haplotype block
for the initial discovery family-based cohort of extremely discor-
dant sibling pairs, these SNPs did not comprise a second block
(block 4) in the unrelated case-control cohort from Central Greece.
Nonetheless, both blocks initially identiﬁed in the discovery cohort
were tested in unconditional logistic regression in the unrelated
case-control cohort. In the Greek population, the single haplotype
block identiﬁed by the Gabriel rule in Haploview was signiﬁcantly
associated with AMD risk. Speciﬁcally, when either comparing
neovascular patients to unaffected patients or separately, to dry
patients, the h2 (GAG) haplotype was signiﬁcantly associated with
AMD risk under a dominant model (OR: 1.470; 95% C.I.:
1.148,1.882; p = 0.0022 and OR: 1.584; 95% C.I.:1.204,2.085;
p = 0.0010, respectively) (Table 8). A second, more modestly asso-
ciated haplotype, h3 (GCG), in this same block (block 1), was also
identiﬁed under a dominant model for both the comparison of neo-
vascular patients to normal subjects and separately for neovascular
patients compared to subjects with dry AMD (AREDS categories 2
and 3) (OR: 1.639; 95% C.I.: 1.032,2.603; p = 0.0363 and OR:
1.718; 95% C.I.:1.01,2.905; p = 0.0432, respectively).
3.7. Interaction of RORA SNPs with CFH and ARMS2/HTRA1
Using conditional logistic regression, interaction was tested be-
tween RORA and CFH, ARMS2/HTRA1 and smoking in the discovery
cohort of 150 extremely discordant sibling pairs. No signiﬁcant
interaction was found between RORA and CFH and separately be-
tween RORA and smoking history. A signiﬁcant interaction was
found between the RORA SNP rs12900948 and the ARMS2/HTRA1
SNPs rs10490924, rs11200638, and rs1049331 (p = 0.0044,
0.0044, and 0.0038 respectively). Based on this data, we incorpo-
rated HTRA1 into the network pathway analysis that included RORA
using IPA’s ‘‘Path Designer” function to explore a hypothetical
molecular means of interaction (Fig. 6). The addition of HTRA1
introduced the following genes: bone morphogenetic protein 4
(BMP4), family with sequence similarity 46, member A (FAM46A),
ﬁbronectin 1 (FN1), growth differentiation factor 5 (GDF5), inter-
leukin 13 (IL13), matrix metallopeptidase 3 (MMP3), matrix metal-
lopeptidase 1 (MMP1), serpin peptidase inhibitor, clade A, member
1 (SERPINA1), transforming growth factor, beta 2 (TGFb2), trans-
forming growth factor, beta 3 (TGFb3) into the analysis (Supple-
mentary Table 5). ARMS2 was not included in network analysis
as it was not available by IPA’s database.
3.8. eQTL analysis
Increasingly, data from GWAS and microarray studies have
been analyzed in combination to uncover expression quantitative
trait loci (eQTL) that relate speciﬁc SNPs to global or tissue speciﬁc
expression of gene transcripts (Cookson, Liang, Abecasis, Moffatt, &
Table 7
UCLR analysis of RORA SNPs in the Greek cohort.
Risk factor Allele Additive model Dominant model Recessive model
Odds ratio (95% C.I.) p-Value Odds ratio (95% C.I.) p-Value Odds ratio (95% C.I.) p-Value
All AMD – neo + dry vs. normal
rs730754 G 1.155 (0.837–1.593) 0.3816 1.391 (0.849–2.278) 0.1905 1.017 (0.586–1.768) 0.9583
rs8034864 A 1.047 (0.729–1.503) 0.8050 0.991 (0.633–1.553) 0.9698 1.371 (0.548–3.434) 0.5001
rs12900948 G 1.345 (0.956–1.894) 0.0891 2.020 (1.172–3.480) 0.0113 1.066 (0.619–1.836) 0.8171
rs17237514 G 1.360 (0.854–2.164) 0.1948 1.355 (0.825–2.227) 0.2303 2.322 (0.257–21.017) 0.4536
rs4335725 A 0.883 (0.622–1.254) 0.4874 0.810 (0.516–1.270) 0.3585 1.026 (0.439–2.399) 0.9523
Neo vs. normal
rs730754 G 1.271 (0.875–1.846) 0.2072 1.965 (1.095–3.526) 0.0235 0.891 (0.475–1.671) 0.7200
rs8034864 A 1.186 (0.778–1.806) 0.4275 1.280 (0.773–2.119) 0.3377 0.991 (0.337–2.917) 0.9873
rs12900948 G 1.502 (0.996–2.264) 0.0523 4.028 (1.924–8.433) 0.0002 0.797 (0.422–1.504) 0.4830
rs17237514 G 1.381 (0.817–2.335) 0.2272 1.425 (0.824–2.462) 0.2048 0.952 (0.059–15.393) 0.9724
rs4335725 A 0.949 (0.643–1.400) 0.7908 0.870 (0.527–1.436) 0.5856 1.190 (0.475–2.983) 0.7101
Neo vs. dry
rs730754 G 1.228 (0.822–1.837) 0.3162 2.156 (1.152–4.033) 0.0163 0.735 (0.378–1.430) 0.3640
rs8034864 A 1.310 (0.838–2.048) 0.2369 1.883 (1.070–3.311) 0.0281 0.507 (0.181–1.420) 0.1964
rs12900948 G 1.190 (0.761–1.859) 0.4456 3.802 (1.725–8.379) 0.0009 0.524 (0.269–1.020) 0.0573
rs17237514 G 0.999 (0.584–1.711) 0.9979 1.136 (0.628–2.054) 0.6735 0.213 (0.022–2.087) 0.1843
rs4335725 A 1.197 (0.770–1.862) 0.4247 1.197 (0.683–2.100) 0.5301 1.511 (0.505–4.518) 0.4600
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by SNP Browser v 1.0.1 (Dixon et al., 2007; Moffatt et al., 2007),
we investigated the association of the RORA SNPs that comprised
our signiﬁcant haplotypes with eQTLs. Of our 5 SNPs, rs8034864,
rs730754, and rs4335725 were present in the database but none
were signiﬁcantly associated with transcript expression according
to the method for calculating signiﬁcance deﬁned by Dixon et al.
(Supplementary Table 6). The interaction between the RORA SNP
rs12900948 and the ARMS2/HTRA1 SNPs led us to investigate the
association of these SNPs, rs10490924, rs11200638, and
rs1049331, with transcript expression. Of the ARMS2/HTRA1 SNPs,
only rs10490924 was present in the database but was not signiﬁ-
cantly associated with the expression of any transcripts (Supple-
mentary Table 6).4. Discussion
In this study, we demonstrate an association between RORA and
AMD. Using a family-based cohort comprised of extremely discor-
dant sibling pairs, we identiﬁed a single RORA SNP, rs4335725, and
two haplotypes which were signiﬁcantly associated with neovas-
cular AMD in FBAT. Study of a smaller discordant sibling popula-
tion [where the index patient had neovascular AMD and the
‘‘control sibling” had a mild dry form of AMD (AREDS category
2)] identiﬁed a second SNP, rs12900948, as being modestly associ-
ated with neovascular AMD. The rs12900948 SNP was part of a
haplotype (GCG) that was identiﬁed as signiﬁcantly associated
with neovascular AMD risk in the initial discovery cohort of extre-
mely discordant sibling pairs in FBAT. In a separate unrelated case-
control cohort from Central Greece, we also identiﬁed rs12900948
and two haplotypes containing this SNP (GAG and GCG) as associ-
ated with neovascular AMD when compared to either unrelated
controls or to unrelated subjects with dry AMD (AREDS categories
2 and 3). Moreover both the rs12900948 and the signiﬁcant haplo-
type (rs730754, rs8034864 and rs12900948) that contained this
SNP were validated prospectively in nested case-control cohorts
from the Nurses’ Health Study and the Health Professionals Fol-
low-up Study (D. Schaumberg et al., personal communication).
It is interesting to note that rs12900948 was signiﬁcant when
comparing neovascular patients to patients with the dry form of
AMD in both the family-based cohort and in the unrelated case-
control cohorts from Central Greece. This may indicate that the riskassociated with rs129000948, or as yet to be discovered variants in
LD with rs129000948, may speciﬁcally relate to the development
of neovascular/advanced AMD.
The signiﬁcant RORA variants and haplotypes associated with
neovascular AMD in both the family-based and unrelated case-
control cohorts occur within the ﬁrst intron of the RORA-001 tran-
script (ENST00000335670), a region that is well conserved across
species, including mouse and rat. Although there is no apparent
functional change, it is interesting to speculate that these or other
undiscovered variations in intron 1, such as an insertion or deletion
resulting in a change in copy number, may change the structure of
the transcript and/or the sequence of unidentiﬁed modifying ele-
ments (e.g. silencers or enhancers) (Hastings, Lupski, Rosenberg,
& Ira, 2009; Lupski, 2007) In turn, these variations could theoreti-
cally inﬂuence gene expression by altering modifying elements,
increasing/decreasing RNA transcript stability, or affecting splicing
with a resultant change in isoform expression (Hollams, Giles,
Thomson, & Leedman, 2002; Maddox et al., 2008; Margulies & Bir-
ney, 2008).
However, it is most likely that the causal sequence change(s) in
this region has yet to be identiﬁed as suggested by analysis of the
signiﬁcant haplotypes. For example, the haplotype containing SNP
rs4335725 was more signiﬁcantly associated with risk of neovas-
cular AMD than rs4335725 alone, suggesting that the causal
variant(s) is likely in LD with this region. Additionally, SNP
rs12900948 was signiﬁcantly associated with neovascular AMD
risk in the discovery cohort as part of a haplotype but not individ-
ually. To begin to resolve these questions, further sequencing of the
exons and the acceptor/donor splice sites adjacent to this region as
well as functionally evaluating each sequence variant for its inﬂu-
ence on gene expression is currently being conducted.
Included in our study is expression analysis of RORA in lympho-
blastoid cell lines. Initial microarray data showed signiﬁcant
changes in both directions, with the majority of probes indicating
decreased expression in affected patients. When evaluating an ex-
panded population (n = 67) with qRT-PCR to clarify and validate
the ﬁnding of the gene expression microarray analysis, we ob-
served an overall trend of decreased RORA expression in affected
patients compared to their unaffected siblings, with statistically
signiﬁcant reduction in RORA gene expression in ﬁve of these fam-
ilies. A limitation of these expression studies is that they did not
assay the individual expression of each of the four RORA isoforms,
which have been shown to have both temporal- and tissue speciﬁc
Fig. 5. Linkage disequilibrium plots for unrelated case-control cohort from Central
Greece. Haplotype blocks were constructed in Haploview using the method
proposed by Gabriel et al. (2002). Boxes were shaded increasingly darker to
represent higher percentage of LD and the numbers listed in each square represent
the D0 (A) and r2 values (B) unless the box is completely shaded in representing
complete LD. A single haplotype block was generated for this cohort.
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et al., 2008; Zhu et al., 2006). Similarly, a limitation of using mRNA
derived from lymphoblastoid cell lines is that while it may be pos-
sible to gain information that reﬂects systemic changes in RORA
expression, these results may be tissue speciﬁc and therefore,
may not be fully reﬂective of expression changes in the retina or
retinal pigment epithelium (RPE) (Nica & Dermitzakis, 2008)Therefore, in order to determine whether or not RORA expression
is truly correlated with neovascular AMD, further studies need to
be conducted on a greater number of patient samples examining
not only the levels of RORA but also the speciﬁc transcripts of RORA
expressed in the various cell types of the retina and cells involved
in the process of neovascularization (including for example, endo-
thelial cells and immune inﬁltrates). In addition, evaluating the
functional consequence of lack of RORA gene expression in a model
system such as mouse may provide further insight into its role in
retinal diseases such as AMD.
RORA has been shown to be ubiquitously expressed but with tis-
sue speciﬁc isoform expression (Chauvet et al., 2002; Liu et al.,
2008; Zhu et al., 2006). Immunohistochemical analysis of normal
mouse retina showed RORA expression in the ganglion cell layer
and inner nuclear layer (Fujieda, Bremner, Mears, & Sasaki, 2009;
Ino, 2004; Steinmayr et al., 1998). Ganglion cell layer neurons have
been shown by Medeiros and Curcio to be reduced by nearly 50% in
eyes of patients with neovascular AMD compared to eyes from
individuals with no AMD (Medeiros & Curcio, 2001). Further, RORA
has been co-localized with cone speciﬁc markers and demon-
strated to play an important role in the development of photore-
ceptors by synergistically regulating the expression of several
cone genes, including S- and M-opsin, along with CRX in the mouse
(Fujieda et al., 2009). Studies using the RORA deﬁcient staggerer
mouse show that RORA is important but not essential for cone
development, as the retina of the staggerer mouse does not exhibit
a difference in cone density nor a difference in other cell types
compared to wild-type mice (Fujieda et al., 2009; Steinmayr
et al., 1998). The role of RORA in the aging retina of the adult stag-
gerer mouse has yet to be established due to lethality in early life
(Fujieda et al., 2009).
In addition to the regulation of cholesterol/lipid metabolism,
data suggest an inhibitory role for RORA in inﬂammation and angi-
ogenesis, cellular processes that have also been implicated in the
development and progression of neovascular AMD (Anderson, Mul-
lins, Hageman, & Johnson, 2002; Besnard et al., 2001, 2002; Boukh-
touche et al., 2004, 2006; Conley et al., 2005; Hageman et al., 2001;
Johnson, 2005; Klein et al., 2003; Lau et al., 2008; Zhu et al., 2006).
Macrophages isolated from the staggerer mouse were shown to
have increased mRNA expression of the inﬂammatory cytokines
interleukin-1 alpha, interleukin-1 beta, interleukin-6, and tumor
necrosis factor-alpha (TNF-a) (Kopmels et al., 1990, 1991, 1992).
This phenotype has been linked to RORA-mediated transcriptional
inhibition of the pro-inﬂammatory transcription factor nuclear fac-
tor kappa B (NFjB) (Delerive et al., 2001). Moreover, RORA isoforms
1 and 4 have been shown to suppress the activation of NFjB by
TNF-a and to suppress TNF-a induced expression of the cell adhe-
sion molecules vascular cell adhesion molecule and the intracellu-
lar adhesion molecule in human endothelial cells (Migita et al.,
2004). Staggerer mice also exhibited decreased angiogenesis in re-
sponse to ischemia induced by femoral artery ligation (Besnard
et al., 2001). It is therefore plausible that genetic variants of RORA
might affect AMD risk through a combination of multiple pathways
in addition to the regulation of cholesterol.
Given the number of processes/pathways in which RORA func-
tions and the signiﬁcance of association between RORA and neo-
vascular AMD, it is unlikely that RORA alone contributes to the
sequelae of events in neovascular AMD but rather that genes reg-
ulated by RORA, or those that regulate RORA, may inﬂuence the dis-
ease. Therefore, although one gene may be modestly associated
with AMD risk, it may be the combination of variants within sets
of genes that can lead to small changes in the way the genes/pro-
teins interact, which, when combined with environmental effects,
can have a huge impact on biological systems culminating in dis-
ease with age (Chen et al., 2008). As a result, the investigation of
Table 8
Haplotype analysis of RORA in the Greek cohort.
Gabriel rule
Order rs730754 rs8034864 rs12900948 UCLR odds ratio (95% C.I.) UCLR p-value
Neovascular + dry vs. normal
Block 1 – additive model
h1 A C A 0.915 (0.803–1.043) 0.1845
h2 G A G 1.093 (0.959–1.246) 0.1845
h3 G C G 1.166 (0.934–1.456) 0.1745
Block 1 – dominant model
h1 A C A 0.960 (0.756–1.220) 0.7396
h2 G A G 1.188 (0.978–1.443) 0.0832
h3 G C G 1.292 (0.877–1.903) 0.1958
Order rs17237514 rs4335725 UCLR odds ratio (95% C.I.) UCLR p-value
Block 4 – recessive model
h1 A G 0.963 (0.657–1.411) 0.8455
h2 A A 0.826 (0.558–1.223) 0.3409
h3 G G 1.266 (0.822–1.948) 0.2843
Order rs730754 rs8034864 rs12900948 UCLR odds ratio (95% C.I.) UCLR p-value
Neovascular vs. normal
Block 1 – additive model
h1 A C A 0.860 (0.734–1.008) 0.0622
h2 G A G 1.162 (0.992–1.361) 0.0622
h3 G C G 1.203 (0.925–1.565) 0.1670
Block 1 – dominant model
h1 A C A 1.063 (0.800–1.413) 0.6724
h2 G A G 1.470 (1.148–1.882) 0.0022
h3 G C G 1.639 (1.032–2.603) 0.0363
Order rs17237514 rs4335725 UCLR odds ratio (95% C.I.) UCLR p-value
Block 4 – recessive model
h1 A G 0.885 (0.579–1.353) 0.5719
h2 A A 0.827 (0.535–1.277) 0.3908
h3 G G 1.150 (0.703–1.881) 0.5774
Order rs730754 rs8034864 rs12900948 UCLR Odds Ratio (95% C.I.) UCLR p-value
Neovascular vs. dry
Block 1 – additive model
h1 A C A 0.890 (0.752–1.055) 0.1788
h2 G A G 1.123 (0.948–1.330) 0.1788
h3 G C G 1.043 (0.786–1.383) 0.7721
Block 1 – dominant model
h1 A C A 1.233 (0.922–1.649) 0.1573
h2 G A G 1.584 (1.204–2.085) 0.0010
h3 G C G 1.718 (1.017–2.905) 0.0432
Order rs17237514 rs4335725 UCLR odds ratio (95% C.I.) UCLR p-value
Block 4 – recessive model
h1 A G 0.818 (0.516–1.297) 0.3931
h2 A A 0.991 (0.617–1.592) 0.9697
h3 G G 0.783 (0.461–1.330) 0.3654
Abbreviation: UCLR, Unconditional Logistic Regression.
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understanding of the pathophysiology of AMD (Figs. 1 and 6).
In this study, we observed a statistically signiﬁcant interaction
between RORA and the ARMS2/HTRA1 locus. This ﬁnding was pro-
spectively validated in two nested case-control cohorts (D.
Schaumberg et al., paper under review). To date, the ARMS2/HTRA1
locus is the region most signiﬁcantly associated with neovascular
AMD (Fisher et al., 2005; Shuler et al., 2007; Zhang et al., 2008),
however, the pathway in which it functions has yet to be eluci-
dated. This interaction suggests that RORA may be functioning in
a similar, an overlapping, or the same pathway as ARMS2/HTRA1and opens up new avenues of investigation based upon the known
roles of RORA.
Similarly, network investigation of RORA, in combination with
HTRA1 and the putative AMD-associated genes discovered by
microarray gene expression analysis, provides further areas of
study interest, some of which have been corroborated indepen-
dently by different experimental means. For example, network
analysis of our signiﬁcant microarray genes (Fig. 1) implicated a
role for transforming growth factor b (TGFb) family members in
AMD. TGFb has been suggested to play a role in AMD by controlling
secretion of vascular endothelial growth factor by RPE cells
Fig. 6. IPA-generated network containing microarray genes that were identiﬁed as signiﬁcant and that showed a greater than 2-fold difference when comparing neovascular
AMD patients and their unaffected siblings with the addition of HTRA1 and HTRA1 interacting molecules. The molecules which are shaded are those that were identiﬁed in our
study. Green indicates down-regulation while red indicates up-regulation when comparing affected to unaffected siblings. HTRA1 is indicated in blue. Solid lines indicate
direct relationships and dotted lines indicate indirect relationships as identiﬁed in previously published literature (http://www.ingenuity.com/index.html). The individual
shapes represent the family of molecule, for example, the shape of RORA indicates a ligand-dependent nuclear receptor. A full listing of these proteins, their ofﬁcial name, and
the family of molecules to which they belong can be found in Supplementary Table 5. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred
to the web version of this article.)
712 A.C. Silveira et al. / Vision Research 50 (2010) 698–715(Nagineni et al., 2003). The addition of HTRA1 to our network anal-
ysis further suggested speciﬁc members of the TGFb family, TGFb2
and TGFb3, that may be involved in AMD pathophysiology (Fig. 6).
This example underscores the importance of examining gene–gene
interaction along with network analysis data as tools in the inves-
tigation of mechanisms underlying AMD.
Another potential result of genetic variation(s) in RORA is the cis
or trans regulation of a nearby locus, a distant gene, or the indirect
regulation of a gene by means of inﬂuencing a regulatory locus (for
review please see Ioannidis, Thomas, & Daly, 2009). In any of these
scenarios one can hypothesize that variation within RORA could af-
fect transcription of another gene(s) that in turn would inﬂuence
the development and progression of AMD. Therefore, we investi-
gated the association of the RORA SNPs found to be signiﬁcant in
our study (either directly or those within a signiﬁcant haplotype)
with eQTLs. Of our 5 SNPs, rs8034864, rs730754, and rs4335725
were present in the database but none were signiﬁcantly associ-
ated with transcript expression (Supplementary Table 6). However,
this is not surprising based on our haplotype analysis demonstrat-
ing that these SNPs are likely not individually causal.
A caveat in the investigation of RORA linked eQTLs is that cur-
rent studies are limited by the available genome wide association
and gene expression microarray platforms, thus limiting the
amount of genetic variation and genes that are assayed. For exam-ple, the most signiﬁcant SNP in the unrelated case-control Greek
population, rs12900948, was not included in the database. As
increasing data becomes available, the study of RORA linked eQTLs
may yield interesting information regarding proteins and path-
ways involved in AMD.
In summary, this is the ﬁrst report of a genetic association be-
tween RORA and neovascular AMD. The identiﬁcation of RORA al-
leles and haplotypes signiﬁcantly associated with neovascular
AMD, coupled with linkage and gene expression data, suggests
an important role for RORA in the aging retina. Additionally, the
overlap between pathways in which RORA plays a role and those
believed to underlie AMD pathophysiology suggests that RORA
and the pathways in which it functions merit further investigation.
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